ArticleBMC medicine2026
Viral shedding dynamics in coxsackievirus A6 hand, foot, and mouth disease: a prospective, individual-level analysis.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCoxsackievirus A6 (CVA6) has emerged as the predominant cause of hand, foot, and mouth disease (HFMD) in China since the introduction of enterovirus A71 (EV-A71) vaccination. A precise definition of the infectious period is critical for effective containment; however, data on the duration and kinetics of CVA6 shedding remain scarce. We therefore aimed to characterize the viral shedding dynamics of CVA6 and to identify the determinants of viral clearance.
methodsWe conducted a prospective longitudinal study enrolling pediatric inpatients with laboratory-confirmed CVA6 HFMD between June 2022 and August 2023. Serial pharyngeal swabs were collected every other day during hospitalization and weekly after discharge until two consecutive negative tests were obtained. Shedding duration was analyzed using Kaplan-Meier estimates and Cox proportional hazards models. Viral load was quantified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and its dynamics were modeled using mixed-effects models.
resultsAmong 88 patients, the median duration of viral shedding was 16 days (95% CI: 14-22), with more than 50% remaining PCR-positive beyond current isolation recommendations. Viral load levels were highest in the first week following symptom onset and tended to show a general progressive decline over the subsequent 5 weeks. Agranulocytosis was associated with prolonged shedding (HR = 0.41, 95% CI: 0.21-0.81, p = 0.010), whereas lymphocytosis accelerated clearance (HR = 1.83, 95% CI: 1.03-3.25, p = 0.039). Elevated aspartate aminotransferase (AST) level was independently associated with higher viral load (β = 0.016, SE = 0.006, p = 0.012).
conclusionsCVA6 infection is characterized by prolonged viral shedding, which is modulated by host immune and hepatic factors. These findings highlight the need for evidence-based, serotype-specific public health guidelines in the post-EV-A71 vaccine era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.